DSpace Repository

Oxfendazole: a promising agent for the treatment and control of helminth infections in humans.

Show simple item record

dc.contributor.author Gonzalez, Armando E.
dc.contributor.author Codd, Ellen E.
dc.contributor.author Horton, John
dc.contributor.author Garcia, Hector H.
dc.contributor.author Gilman, Robert H.
dc.date.accessioned 2019-03-05T15:25:03Z
dc.date.available 2019-03-05T15:25:03Z
dc.date.issued 2018
dc.identifier.uri https://hdl.handle.net/20.500.12866/5935
dc.description.abstract Introduction: Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole’s nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans. en_US
dc.language.iso eng
dc.publisher Taylor & Francis
dc.relation.ispartof urn:issn:1744-8336
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject animal en_US
dc.subject animal parasitosis en_US
dc.subject Animals en_US
dc.subject anthelmintic agent en_US
dc.subject Anthelmintics en_US
dc.subject antiparasitic drugs en_US
dc.subject benzimidazole derivative en_US
dc.subject benzimidazoles en_US
dc.subject Benzimidazoles en_US
dc.subject bioavailability en_US
dc.subject Biological Availability en_US
dc.subject cysticercosis en_US
dc.subject drug bioavailability en_US
dc.subject drug effect en_US
dc.subject drug efficacy en_US
dc.subject drug safety en_US
dc.subject drug structure en_US
dc.subject evidence based medicine en_US
dc.subject farm animal en_US
dc.subject half life time en_US
dc.subject Half-Life en_US
dc.subject helminthiasis en_US
dc.subject Helminthiasis en_US
dc.subject Helminthiasis, Animal en_US
dc.subject helminths en_US
dc.subject human en_US
dc.subject Humans en_US
dc.subject hydatid disease en_US
dc.subject infection control en_US
dc.subject larval stage en_US
dc.subject nonhuman en_US
dc.subject outcome assessment en_US
dc.subject oxfendazole en_US
dc.subject Oxfendazole en_US
dc.subject parasite transmission en_US
dc.subject parasitology en_US
dc.subject Peru en_US
dc.subject pig en_US
dc.subject Review en_US
dc.subject Zoonoses en_US
dc.subject zoonosis en_US
dc.title Oxfendazole: a promising agent for the treatment and control of helminth infections in humans. en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1080/14787210.2018.1555241
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.01
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.02
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics